Search results
Results from the WOW.Com Content Network
Generic Xarelto Availability. Last updated on Nov 6, 2024. Xarelto is a brand name of rivaroxaban, approved by the FDA in the following formulation(s): XARELTO (rivaroxaban - for suspension;oral) Manufacturer: JANSSEN PHARMS Approval date: December 20, 2021 Strength(s): 1MG/ML ; XARELTO (rivaroxaban - tablet;oral) Manufacturer: JANSSEN PHARMS
Mumbai, Baltimore, January 23, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto ...
Currently a brand-name-only product, it may be a few years until a generic version of Xarelto becomes available. There are many ways to save on Xarelto. If you’re eligible, a manufacturer savings card can help you access Xarelto for as little as $10 per month.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 28, 2025. This may change due to patent challenges or generic licensing. Annual sales in 2021 were $6.3bn, indicating a strong incentive for generic entry (peak sales were $7.2bn in 2020).
There is no estimated timeframe for generic Xarelto to become available. However, the drug patents for Xarelto are expected to expire sometime in 2024, which is the earliest time Xarelto generic will become available for sale.
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] . Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [8] . It is taken by mouth. [8]
Xarelto FDA Approval History. Last updated by Judith Stewart, BPharm on Dec 26, 2021. FDA Approved: Yes (First approved July 1, 2011) Brand name: Xarelto Generic name: rivaroxaban Dosage form: Tablets and Oral Suspension Company: Johnson & Johnson Innovative Medicine
Based on its patents and exclusivities, its generic launch date is estimated to be Jul 31, 2039. Details of Xarelto's patents and their expiration are given in the table below. These drug patents protect the active ingredient (API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
Global pharma major Lupin Limited (Lupin) announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for rivaroxaban tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto tablets, 2.5 mg, 10 mg, 15 mg, and 20 mg, of ...
Rivaroxaban is the generic name for Xarelto. Medicare covers the cost of the prescription medication, including Xarelto, under certain conditions.